First test of new weapon against Mosquito-Borne virus
NCT ID NCT04441905
Summary
This was an early-stage study to check the safety of a new antibody drug, SAR440894, in healthy people. The goal is to see if this antibody could eventually be used to prevent infection from the Chikungunya virus, which is spread by mosquitoes. Forty-two healthy adults received a single dose of the antibody or a placebo via an IV drip, and researchers closely monitored them for side effects and how the drug moved through their bodies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit
Durham, North Carolina, 27710, United States
-
PPD - Austin Clinical Research Unit
Austin, Texas, 78744-1645, United States
-
Pharmaceutical Product Development - Orlando Clinical Research Unit
Orlando, Florida, 32806, United States
Conditions
Explore the condition pages connected to this study.